13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q3 2023 · Filed August 9, 2023 · Accession 0000950123-23-007098
Total Value
$84.3M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $28.0M | 33.22% |
| 2 | CRISPR Therapeutics AG | CRSP | 498,558 | $28.0M | 33.20% |
| 3 | Adverum Biotechnologies, Inc. | 00773U108 | 5,068,233 | $8.1M | 9.56% |
| 4 | Gritstone Oncology, Inc. | 39868T105 | 3,561,150 | $6.9M | 8.24% |
| 5 | CymaBay Therapeutics, Inc. | 23257D103 | 543,753 | $6.0M | 7.06% |
| 6 | Passage Bio, Inc. | PASG | 4,959,769 | $4.7M | 5.54% |
| 7 | Aligos Therapeutics, Inc. | ALGS | 2,320,381 | $2.3M | 2.67% |
| 8 | Minerva Surgical Inc. | 60343F106 | 1,673,700 | $428,802 | 0.51% |